Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Single-arm, Open-label Phase II Study of the Safety of Lenalidomide Monotherapy and Markers for Disease Progression in Patients With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Associated With an Isolated Deletion 5q Cytogenetic Abnormality (Del 5q).

Next Previous
Search
Trial Profile

A Multicenter, Single-arm, Open-label Phase II Study of the Safety of Lenalidomide Monotherapy and Markers for Disease Progression in Patients With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Associated With an Isolated Deletion 5q Cytogenetic Abnormality (Del 5q).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms LE-MON-5; LEMON5; MDS-LE-MON-5

    • Most Recent Events

    • 01 Jun 2021 Results (n=51) published in the Annals of Hematology
    • 10 Dec 2013 Results assessing changes in telomere length in lymphocytes and granulocytes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Jul 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003746).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top